Pharmafile Logo
Pharmafocus logo
Advanced Search

Farnesoid X Receptor

Showing 1 posts of 1 posts found.

Gilead acquires Phenex liver disease drugs

January 7, 2015
Research and Development, Sales and Marketing Farnesoid X Receptor, Gilead, liver, nafld, nash, phenex

Gilead Sciences has acquired Phenex Pharmaceuticals’ development programme for the treatment of serious liver diseases. The US biopharma firm will …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026